 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
26 News |  |
- || Anaferon / Materia Medica, EastGate Biotech
Por cierto no hablo solo por hablar, eh salido"positivo"3 veces creo una en cada"ola"ni yo ni mis niños ni esposa tenemos "secuelas",por supuesto q no estamos vacunados y no usamos cubrebocas,si reforzamos sistema immunologico, ejercicio, sol, y 0 miedo. Dales anaferon infantil (Twitter) - May 20, 2022
- || Anaferon / Materia Medica, EastGate Biotech
Clinical, Journal: The level of natural autoantibodies to IFN-gamma in varicella infections treated with antiviral drug Anaferon for Children: a pilot study. (Pubmed Central) - May 20, 2021
In the AC group, the NAbs level observed on days 5 and 10 decreased significantly to a level of 154 × 10 U/ml, whereas in the placebo group it continued to rise in a time-dependent manner reaching 229 × 10 U/ml on day 10. Our findings suggest that treatment with AC is characterized by "normalization" of the anti-IFN-γ NAbs levels in patients with varicella infection.
- | Copegus (ribavirin) / Bausch Health, Anaferon / Materia Medica
Clinical, Journal: The efficacy of anti-viral therapy and serotherapy of tick-borne encephalitis in children (Pubmed Central) - Nov 8, 2019
In group 4, symptoms increased in 72.7%, while virus replication was preserved and atrophic changes in the CNS increased on MRI. Antiviral therapy (ribavirin, IFN-α2 and release of active antibodies to gamma interferon -anaferon children) has the highest efficacy when prescribed for the first 5 days, while IgG and ribonuclease have insufficient efficacy in TBEV.
- Anaferon / Materia Medica
The results of a randomized clinical trial of the efficacy of the antibodies-based drug in influenza and acute respiratory viral infections in children (TP-21) - Aug 26, 2019 - Abstract #ERS2019ERS_1069;
To investigate the efficacy of Anaferon for Children (AC), based on released-active form of antibodies to interferon-gamma, in children with ARVI, i.a. influenza...As a part of ARVI/influenza complex therapy, AC promotes recovery and elimination of influenza A/B viruses from respiratory epithelial cells. The lack of information on influenza vaccination is the limitation of this study.
- | Anaferon / Materia Medica
Journal: Drug discovery today: no molecules required. (Pubmed Central) - Aug 23, 2019
The lack of information on influenza vaccination is the limitation of this study. No abstract available
- | Anaferon / Materia Medica, EastGate Biotech
Trial completion: Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI (clinicaltrials.gov) - Aug 6, 2019
P4, N=1036, Completed, Sponsor: Materia Medica Holding
No abstract available Active, not recruiting --> Completed
- ||| Anaferon / Materia Medica, EastGate Biotech
Enrollment closed: Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI (clinicaltrials.gov) - May 20, 2019
P4, N=1036, Active, not recruiting, Sponsor: Materia Medica Holding
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Anaferon / Materia Medica, EastGate Biotech
Trial completion, Trial completion date, Trial primary completion date: Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections (clinicaltrials.gov) - May 1, 2019
P4, N=204, Completed, Sponsor: Materia Medica Holding
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial completion date: Aug 2019 --> Mar 2019 | Trial primary completion date: Aug 2019 --> Mar 2019
- | Anaferon / Materia Medica, EastGate Biotech
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI (clinicaltrials.gov) - Oct 29, 2018
P4, N=1036, Recruiting, Sponsor: Materia Medica Holding
Recruiting --> Completed | Trial completion date: Aug 2019 --> Mar 2019 | Trial primary completion date: Aug 2019 --> Mar 2019 Completed --> Recruiting | N=710 --> 1036 | Trial completion date: Apr 2018 --> Jul 2019 | Trial primary completion date: Apr 2018 --> Jul 2019
- | Anaferon / Materia Medica, EastGate Biotech
New P4 trial: Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections (clinicaltrials.gov) - Oct 15, 2018
P4, N=204, Recruiting, Sponsor: Materia Medica Holding
- |||| Anaferon / Materia Medica, EastGate Biotech
Trial completion: Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI (clinicaltrials.gov) - Jun 14, 2018
P4, N=710, Completed, Sponsor: Materia Medica Holding
Completed --> Recruiting | N=710 --> 1036 | Trial completion date: Apr 2018 --> Jul 2019 | Trial primary completion date: Apr 2018 --> Jul 2019 Active, not recruiting --> Completed
- ||| Anaferon / Materia Medica, EastGate Biotech
Enrollment closed: Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI (clinicaltrials.gov) - Feb 1, 2018
P4, N=710, Active, not recruiting, Sponsor: Materia Medica Holding
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Anaferon / Materia Medica, EastGate Biotech
Trial primary completion date: Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children (clinicaltrials.gov) - Jan 17, 2018
P4, N=672, Recruiting, Sponsor: Materia Medica Holding
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> May 2018
- ||||| Anaferon / Materia Medica, EastGate Biotech
Enrollment open, New P4 trial: Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI (clinicaltrials.gov) - Oct 4, 2017
P4, N=710, Not yet recruiting, Sponsor: Materia Medica Holding
Trial primary completion date: Jan 2018 --> May 2018 Not yet recruiting --> Recruiting
- |||||||||| Anaferon / Materia Medica, EastGate Biotech
New P3 trial: Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections (clinicaltrials.gov) - May 22, 2017
P3, N=142, Completed, Sponsor: Materia Medica Holding
- || Anaferon / Materia Medica, EastGate Biotech
Trial primary completion date: Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children (clinicaltrials.gov) - Jan 30, 2017
P4, N=672, Recruiting, Sponsor: Materia Medica Holding
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Jan 2018
- |||| Anaferon / Materia Medica, EastGate Biotech
Enrollment open: Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children (clinicaltrials.gov) - Oct 10, 2014
P4, N=672, Recruiting, Sponsor: Materia Medica Holding
Trial primary completion date: Dec 2015 --> Jan 2018 Active, not recruiting --> Recruiting
- ||||| Anaferon / Materia Medica, EastGate Biotech
New P4 trial: Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children (clinicaltrials.gov) - Feb 24, 2014
P4, N=672, Active, not recruiting, Sponsor: Materia Medica Holding